

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Under 37 CFR 1.97(b) or 1.97(c) OCT 14 2005		Docket No. 114309-1007			
In Re: Application Of Gerald Horn					
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/854,414	May 10, 2001	Z. Fay	24573	1614	7675
Title: OPHTHALMIC FORMULATIONS COMPRISING IMIDAZOLINE					
<p style="text-align: center;">Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p> <p style="text-align: center;">37 CFR 1.97(b)</p> <p>1. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p style="text-align: center;">37 CFR 1.97(c)</p> <p>2. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p style="margin-left: 40px;"><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center;">OR</p> <p style="margin-left: 40px;"><input checked="" type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>					

P10A/REV05

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Docket No.
114309-1007

OCT 14 2005

(Under 37 CFR 1.97(b) or 1.97(c))

Re Application: Gerald Horn

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/854,414	May 10, 2001	Z. Fay	24573	1614	7675

Title: OPTHALMIC FORMULATIONS COMPRISING IMIDAZOLINE

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below.
- ☒ Charge the amount of \$180.00
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

October 11, 2005

(Date)

Signature of Person Mailing Correspondence

Heather Foster

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: October 11, 2005

Thomas C. Basso (46,541)
Cust. No. 29175

CC:

P10A/REV05



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gerald Horn
Appl. No.: 09/854,414
Conf. No.: 7675
Filed: May 10, 2001
Title: OPHTHALMIC FORMULATIONS COMPRISING IMIDAZOLINE
Art Unit: 1614
Examiner: Z. Fay
Docket No.: 114309-1007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form be made during the course of examination of the above-identified application for United States patent. Pursuant to 37 C.F.R. 1.98, copies of all foreign patent documents and non-patent documents are enclosed.

U.S. PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Inventor</u>
6,730,691	May 4, 2004	Galín

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC


BY 

Thomas C. Basso (46,541)
Cust. No. 29175

Dated: October 11, 2005

10/17/2005 YPOLITE1 00000048 021818 09854414

02 FC:1806 180.00 DA



INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Atty Docket No. 114309-1007	Application No. 09/854,414
PTO Form 1449		Applicant Gerald Horn	
		Filing Date May 10, 2001	Group 7675

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
	6,730,691	May 4, 2004	Galin			

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner's Initials	

Examiner: /Zohreh Fay/ (05/11/2011)	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	